Media

Key Milestones

PRINCETON, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE)

Logic Biosciences Announces International Award for LBS-101 Program

July 29, 2018 08:00 AM Eastern Daylight Time
NEWARK, N.J.--(BUSINESS WIRE)--Logic Biosciences, Inc., a development-stage pharmaceutical company, today announced that its lead product candidate, LBS-101, has been recognized with an Innovation in Oral Care Award from the International Association for Dental Research (IADR). LBS-101 is a long-acting topical formulation of a novel salt of bupivacaine, being developed for oral pain from mouth ulcers (oral mucositis) secondary to chemotherapy or radiation therapy for cancer. The award also includes research funding to the University of Connecticut (UConn), to advance the drug development program. This funding is supported by GlaxoSmithKline, through an unrestricted grant to the IADR. Awardees are selected by a scientific review panel of the IADR. The award was given at the IADR conference held in London, England from July 25-28, 2018.

Read More
PRINCETON, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE)

Cellix Biosciences Announces Regulatory Pathway Confirmation for CLX-106 in the U.S.

July 11, 2018 02:09 PM Eastern Daylight Time
NEWARK, N.J.--(BUSINESS WIRE)--Cellix Biosciences Inc. (“Cellix Bio”), a development-stage pharmaceutical company, today announced confirmation from the U.S. Food and Drug Administration (FDA) that the 505(b)(2) regulatory pathway is appropriate for development of CLX-106 for treatment of relapsing-remitting multiple sclerosis (RRMS). CLX-106 is a novel molecular conjugate designed to deliver an optimal therapeutic profile of monomethyl fumarate (MMF) for RRMS. MMF is the active moiety of dimethyl fumarate (DMF), an approved RRMS therapy that achieved global sales of over $4 billion in 2016.

Read More
PRINCETON, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE)

V ClinBio Acquires 49.98% Stake in Cellix to Advance Synergix, a Transformative Pro-drug Technology Platform

PRINCETON, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- V ClinBio Inc., an innovative biopharmaceutical company focused on transforming existing compounds into differentiated new therapeutics, today announced that it has acquired a 49.98% equity stake in Cellix Bio, an innovative drug design and development company.

Read More
Research in International Immunopharmacology

Research in International Immunopharmacology

Cellix Bio Publishes CLX-103 Research in International Immunopharmacology: Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of Inflammatory Bowel Diseases.

Read More
Research in International Immunopharmacology

Logic Biosciences, Inc.

Cellix Bio and Logic Biosciences, Inc., Joint Venture is focused to develop and commercialize novel therapies and targeted delivery formulations for the management of Pain in various therapeutic indications such as Oral Mucositis and Post-Operative Pain.

Read More
Research in International Immunopharmacology

SPARK Technology

Cellix Bio’s CLX-117 pipeline lead candidate qualifies for UConn SPARK Technology Commercialization Fund Program 2016 with the investigative supervision of Dr. Rajesh V Lalla. The award aims to help investigators from UConn-Storrs and UConn Health (UCH) move ideas into the earliest stages of commercialization and development.

Read More
Research in International Immunopharmacology

VClinBio, Inc.

Cellix Bio and VClinBio, Inc., Collaboration is focused to develop and commercialize novel therapies for the treatment of Multiple Sclerosis and Psoriasis. CLX-106 pipeline lead candidates comprises of Novel MonoMethylFumarate Glyceryl Ester molecular entities.

Read More
Research in International Immunopharmacology

New Jersey Medical School, Rutgers

Cellix Bio and New Jersey Medical School, Rutgers; collaboration is focused to screen novel anti-fungal compounds developed and patented by Cellix Bio. These novel therapies are focused to address the drug resistance in pathogenic fungal infections.

Research in International Immunopharmacology

Excellence Award

Cellix Bio bags 2017 Fastest Growing Indian Company Excellence Award. The award will be presented during the National Seminar & Awards Ceremony on “Individual Achievements & National Development” at New Delhi.

Research in International Immunopharmacology

Texas A&M University

Cellix Bio and Texas A&M University collaboration is focused to screen Gastro-Intestinal Tolerable NSAIDs with improved efficacy and safety profile. Cellix Bio’s Patented Platform Technology driven Diclofenac Novel Long Chain Fatty acid conjugate had low GI ulceration with improved safety and tolerability profile. The collaboration is also extended to investigate the Novel Sulindac and Eflornithine novel molecular conjugates for the effective treatment of GI Polyps.

Strong scientific platform ! Synergix